Ironwood Pharmaceuticals, Inc. — 2014 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2014. The filing also presents unaudited fourth-quarter results. Financial amounts below are in U.S. dollars; annual financial statement amounts are generally in millions unless stated otherwise.
Business context
Ironwood is a human therapeutics company focused on gastrointestinal medicines and guanylate cyclase pathways. Its only marketed product was linaclotide, sold in the U.S. and Mexico as LINZESS and in certain other markets as CONSTELLA. In the U.S., Ironwood and Actavis share development and commercialization costs and net profits or losses equally; outside the U.S., commercialization is largely conducted through partners.
Key financial metrics
| Metric | 2014 | 2013 |
|---|---|---|
| Collaborative arrangements revenue | $76.4 million | $22.9 million |
| Total costs and expenses | $245.8 million | $274.9 million |
| Operating loss | $169.4 million | $252.0 million |
| Net loss | $189.6 million | $272.8 million |
| Net loss per share, basic and diluted | $1.39 | $2.35 |
| Cash, cash equivalents and available-for-sale securities at year-end | $248.3 million | $197.6 million |
| Net cash used in operating activities | $155.6 million | $273.4 million |
| Total assets / stockholders’ equity at year-end | $333.5 million / $88.6 million | $279.0 million / $38.2 million |
Revenue is reported as collaborative arrangements revenue, including Ironwood’s share of U.S. LINZESS net profits; the filing does not present a conventional product-sales gross margin. A meaningful overall margin measure is therefore not provided.
Fourth quarter: Collaborative arrangements revenue was $38.1 million versus $5.0 million in Q4 2013; net loss was $37.6 million versus $52.0 million. Q4 2014 costs and expenses were $71.2 million, compared with $51.8 million in Q4 2013. The annual report’s quarterly figures are unaudited.
Liquidity, cash flow and debt
- Year-end current assets were $289.7 million and current liabilities were $60.5 million. The company reported working capital of $236.4 million excluding deferred revenue.
- Operating cash outflow improved to $155.6 million from $273.4 million. Investing activities used $56.6 million; financing activities provided $210.9 million, largely from the February 2014 stock offering, which generated $190.4 million net.
- Year-end notes payable were $173.6 million, including current and long-term portions; capital lease obligations were $3.7 million. The notes bear 11% annual interest and require quarterly payments tied to the greater of 7.5% of preceding-quarter U.S. LINZESS net sales or accrued interest. Principal was $1.2 million lower after payments through year-end; legal maturity is on or before June 15, 2024.
- Management stated that available cash and investments were expected to fund projected operating needs for at least the next 12 months, while cautioning that actual cash use could be higher than forecast.
Changes versus prior periods and unusual items
- Collaborative revenue rose 234% year over year, primarily because Ironwood’s share of U.S. LINZESS net profits increased by approximately $44.7 million. Other contributors included a $10.2 million Astellas development milestone and $2.6 million of AstraZeneca-related license revenue; lower API shipments partly offset the increase.
- Net loss narrowed by $83.2 million. Total costs and expenses declined 10.6%, including the absence of 2013 collaboration expense as U.S. LINZESS economics shifted to a net profit-share payment to Ironwood.
- Cost of revenue included a $20.3 million inventory write-down, reducing inventory to an estimated net realizable value of about $5.0 million. The write-down reflected weaker European demand forecasts, including the suspension of CONSTELLA commercialization in Germany after reimbursement-price negotiations failed.
- Ironwood reduced its workforce by approximately 10% in 2014 and recorded about $4.3 million in related costs; payments were completed by year-end. It also raised $190.4 million net through an equity offering, increasing shares outstanding.
- Management reported a $967.4 million accumulated deficit and expected continued operating losses and substantial R&D and commercialization spending for the foreseeable future.
Outlook, pipeline and principal risks
- No specific revenue, earnings or product-sales guidance was provided. Management said it does not intend to issue quarterly or annual earnings guidance if and when the company becomes profitable.
- Development activity included a Phase III U.S. trial of a lower 72 mcg linaclotide dose for adult CIC, a Phase II trial for opioid-induced constipation, and Phase III studies in China and Japan. IW-9179 was being studied for diabetic gastroparesis; the filing reported mixed early functional dyspepsia findings, with diarrhea the most common adverse event. After year-end, Ironwood reported encouraging exploratory Phase IIa results for IW-3718 in refractory GERD and initiated a Phase I study of sGC candidate IW-1973.
- Key risks include dependence on U.S. LINZESS performance and partner execution; pricing, reimbursement and market access; product safety and post-approval pediatric studies; clinical and regulatory failure; patent challenges and competition; and reliance on third-party manufacturing and supply. The company also cautioned that its ability to meet debt payments depends partly on cash flows under the Actavis collaboration.
- Ironwood disclosed no material legal proceedings in Item 3. It reported effective disclosure controls and internal control over financial reporting, with an unqualified audit opinion on the financial statements and internal controls.
Important facts for investors to verify
- Whether U.S. LINZESS sales and Ironwood’s resulting 50% net-profit share can grow enough to reduce cash burn and support debt service.
- Whether European demand, pricing and reimbursement improve, and whether the inventory write-down signals further supply or forecast risk.
- The assumptions behind management’s at-least-12-month liquidity estimate, including development spending, commercial costs and partner settlements.
- Terms and payment mechanics of the 11% notes, including the sales-linked quarterly payments, covenants and potential shortfall obligations.
- Clinical progress, safety findings and regulatory requirements for linaclotide and pipeline candidates, as well as patent protection and partner performance.